21 Jun 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Takeda Pharmaceutical and Pfizer Japan have concluded an agreement that, as of December 31, 2012, Takeda will cease distribution of 13 out of the 15 Pfizer products that it previously procured from Wyeth (which was acquired by Pfizer in 2009) and currently distributes under an exclusive distribution agreement with Pfizer. Pfizer, the manufacturer of the products, will begin selling them thereafter. Takeda will continue to distribute the pneumococcus vaccine Prevenar for infants and young children and hemophilia B drug BeneFIX after January 2013.
Aside from this exclusive distribution agreement, the two companies agreed in February 2011 to extend the term of co-promotion agreement of the rheumatoid arthritis (RA) drug Enbrel (generic name: etanercept), the marketing of which Takeda will continue.
Takeda and Pfizer will remain committed to the prevention and treatment of diseases by providing drugs that meet the needs of patients and medical professionals through their successful partnership.
The 13 products, the marketing of which by Takeda will terminate on December 31, 2012 and be commenced by Pfizer in January, 2013.